TSHA

Taysha Gene TherapiesD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$7.20

Analysis reference price unavailable

Analysis 2026-10-15 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$4.10

Analysis reference price unavailable

Analysis 2026-10-15 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$1.40

Analysis reference price unavailable

Analysis 2026-10-15 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-10-15

AI commentary

The evidence supports a cautiously positive clinical-development view, not an imminent approval thesis. Taysha's October 1 notice described October 15–17 presentations as encores of previously shared data, not a new readout. https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-multiple-encore-presentations No verified post-release price reaction, current options or short-interest measure, social coverage, or analyst revision series is available; the numeric sentiment fields therefore should not be interpreted as measured neutral readings.

RankAlpha Sentiment Codex - 2026-10-15

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-12-31catalystTSHA-102 manufacturing qualificationHigh impact

Taysha expects to complete its BLA-enabling process performance qualification campaign in Q4 2026. Completion would reduce manufacturing execution risk, but would not establish clinical efficacy or FDA approval. [#8-K-2026-08-11] [#SEC-8K-2026-08-11] https://www.sec.gov/Archives/edgar/data/1806310/000119312526344594/d161230dex991.htm

2027-06-30eventREVEAL pivotal six-month interim dataHigh impact

The company expects topline results in 1H 2027 after all 17 dosed pivotal-trial patients reach six months of follow-up. The single-arm developmental-milestone response is the central efficacy test; encouraging earlier Phase 1/2 results do not guarantee replication. [#8-K-2026-08-11] [#SEC-8K-2026-08-11] https://www.sec.gov/Archives/edgar/data/1806310/000119312526344594/d161230dex991.htm

2027-06-30catalystFDA feedback on the TSHA-102 BLA pathwayHigh impact

Taysha expects FDA feedback in 1H 2027 on whether the REVEAL interim analysis can support a BLA submission. Its ASPIRE safety study is intended to support a potential label covering patients aged two and older; neither the submission pathway nor label breadth is assured. [#8-K-2026-08-11] [#SEC-8K-2026-08-11] https://www.sec.gov/Archives/edgar/data/1806310/000119312526344594/d161230dex991.htm

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-10-15 • Updated nightlySource: Internal modelMethodology